Neurotrope Bioscience to Release Results From Phase 2 Clinical Trial in Moderate to Severe Alzheimer's Disease on May 1, 2017

NEW YORK, April 28, 2017 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP),  a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, will issue a press release announcing results of top-line data from its 148 patient, Phase 2 clinical trial in moderate to severe Alzheimer's Disease, on Monday May 1, 2017, at  6:30 am, Eastern Time.  A conference call will follow at 8:30 am Eastern Time on that date.

The dial-in information to access the live call is listed below:

Participant Toll Free Dial-In Number:            (877) 245-7303
Participant International Dial-In Number:       (478) 219-0731
Conference ID:                                            16070779

The dial-in information to access the call replay, available for 30 days after the live call, is listed below:

Replay Toll Free Dial-In Number:                  (800) 585-8367
Replay International Dial-In Number:             (404) 537-3406
Conference ID:                                            16070779

Callers should dial in approximately 10 minutes before the live call begins.

About Neurotrope

Neurotrope is at the forefront of developing a novel therapy to treat and potentially reverse moderate to severe Alzheimer's dementia and other neurodegenerative diseases. The Company's world-class science is a paradigm shifting approach that treats some of the underlying causes of Alzheimer's disease.

The scientific basis of our treatment is activation of Protein Kinase C isozymes ε and α by Bryostatin-1, a natural product, which in mouse Alzheimer's disease models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's dementia.

Neurotrope has conducted a Phase 2 trial of Bryostatin-1 in the treatment of moderate to severe Alzheimer's dementia, as well as preclinical studies of Bryostatin-1 as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease and Rett Syndrome, three rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for Bryostatin-1 as a treatment for Fragile X Syndrome.  Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 study and further studies, and continued development of use of Bryostatin-1 for Alzheimer's dementia and other cognitive diseases.  Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over.  There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized.  Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand the Company's business,  significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2016. The Company does not undertake to update these forward-looking statements.

Please visit www.neurotropebioscience.com for further information.

For additional information, please contact:

Neurotrope Bioscience, Inc.
Jeffrey Benison, Director of Corporate Communications
212.334.8709 or 516.286.6099
jbenison@neurotropebioscience.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurotrope-bioscience-to-release-results-from-phase-2-clinical-trial-in-moderate-to-severe-alzheimers-disease-on-may-1-2017-300447822.html

SOURCE Neurotrope, Inc.